 - QTc interval 480 milliseconds Patients with any cardiac arrhythmia requiring anti-arrhythmic medication Patients who have had a history of coronary artery disease CAD eg. angina Canadian class II-IV see appendix G In any patient whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiopathy to define whether or not CAD is present Patients who have had a myocardial infarction within 12 months of study entry. Patients with an ECG recorded at screening showing evidence of cardiac ishemia ST depression of 2mm. If in any doubt, the patient should have a stress imaging study and if abnormal, angiograpphy to define whether or not CAD is present Patients with congestive heart failure that meets New York heart Association NYHA Class II to IV see appendix F definitions andor ejection fraction 40 by MUGA scan or 50 by echocardiogram andor magnetic resonance imaging MRI Patients with a history of sustained VT,VF,Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator AICD Patients with a hypertrophic cardiomelagy or restrictive cardiomyopathy from prior treatment or other causes in doubt, see ejection fraction criteria above Patients with uncontrolled hypertension ie 16095 Concomitant use of medications which may cause a prolongation of QTQTc Concomitant use of medications that are inhibitors of the cytochrome P-450 isoenzyme CYP 3A4 Absolute neutrophil count ANC 1.5 X 109 cellsL Platelet count 75 x 109 cellsL Serum creatinine concentration 2 mgdL or creatinine clearance 40mLmin AST aspartate aminotransferase and alanine aminotransferase ALT 2.0 x ULN or 5 X ULN in presence of demonstable liver metastasis Bilirubin concentration 1.25 x ULN or 2.0 x ULN in presence of demonstrable liver metastases Serum potassium 4.0mEqL and serum magnesium 2.0 mgdL Failure to recover of any drug-related non-hematological toxicity to grade 1 oe less or to baseline values unless otherwise indicated Concomitant use of warfarin due to a potentialdrug to drug interaction with depsipeptide Patient is pregnant or nursing Patient had been on prior Gloucester-sponsored depsipeptide clinical trial, left the trial and then received alternative neoplastic therapy 